Φορτώνει......
Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
Nintedanib is a tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis (IPF). We investigated the cardiovascular safety of nintedanib using pooled data from the TOMORROW and INPULSIS trials. Cardiovascular events were assessed post hoc in patients with a history of atherosclerotic car...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Eur Respir J |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
European Respiratory Society
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6766682/ https://ncbi.nlm.nih.gov/pubmed/31285303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.01797-2018 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|